基于骨免疫学论中医药抑制类风湿关节炎骨破坏的研究进展  

Traditional Chinese Medicine in Inhibiting Bone Destruction in Rheumatoid Arthritis Based on Bone Immunology Theory:A Review

作　　者：夏璇[1] 陈杰君 张磊[1,2] 王茂杰[1] 黄闰月[1] 储永良[1,2] XIA Xuan;CHEN Jiejun;ZHANG Lei;WANG Maojie;HUANG Runyue;CHU Yongliang(The Second Affiliated Hospital of Guangzhou University of Chinese Medicine/Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou 510120,China;Zhuhai Hospital of Guangdong Provincial Hospital of Traditional Chinese Medicine,Zhuhai 519015,China)

机构地区：[1]广州中医药大学第二附属医院/广东省中医院,广州510120 [2]广东省中医院珠海医院,珠海519015

出　　处：《世界中医药》2024年第15期2352-2356,共5页World Chinese Medicine

基　　金：国家自然科学基金面上项目(82274421);广东省中医院中医药科学技术研究专项(YN2020QN16)。

摘　　要：类风湿关节炎(RA)是一种以滑膜炎、软骨与骨破坏为主要病理表现的自身免疫性疾病,致残率较高。RA免疫及炎症反应与骨细胞代谢互为影响,其核心环节为破坏机体核因子κB受体活化因子配体/核因子κB受体活化因子/骨保护素(RANKL/RANK/OPG)信号通路的平衡,导致成骨细胞减少,以及破骨细胞凋亡减退及异常活化。西药目前以抑制炎症反应及相关细胞因子分泌,减缓疾病进展,但长期使用其不良反应难以忽视。中医药在防治骨破坏中研究逐步深入,但在基础及临床研究方面仍存在一定局限性。Rheumatoid arthritis(RA)is an autoimmune disease characterized by synovitis,cartilage,and bone destruction,with a high rate of disability.The immune and inflammatory responses in RA interact with bone cell metabolism,with a key mechanism involving the imbalance in the receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin(OPG)signaling pathway.This imbalance leads to decreased osteoblasts and increased osteoclast apoptosis and abnormal activation.While western medicine primarily focuses on inhibiting inflammatory responses and related cytokine secretion to slow disease progression,long-term use is associated with notable adverse effects.Research into traditional Chinese medicine(TCM)for preventing and treating bone destruction in RA has advanced,but both basic and clinical research still face certain limitations.

关 键 词：骨免疫学 中医药 类风湿关节炎 骨破坏 炎症反应 核因子ΚB受体活化因子 核因子ΚB受体活化因子配体 骨保护素 

分 类 号：R242[医药卫生—中医临床基础]